case_images: PMC5045905_01
case_images: Changes in right visual acuity and frequency of ocular attacks during treatment.. Notes: Visual acuity remained at 1.0, and no ocular attacks occurred after switching to adalimumab. Black arrowheads indicate the timing of ocular attacks. *The frequency of attacks was converted into an annual frequency. Data in parentheses indicates the actual frequency of attacks during representative treatments.
case_images: imcrj-9-301Fig1.jpg
case_images: PMC5045905_01_imcrj-9-301Fig1.jpg
case_images: f1-imcrj-9-301
case_images: After switching to adalimumab, uveitis was well controlled, right visual acuity remained at 1.0, and ocular inflammatory attacks did not occur during 2 years of follow-up (Figure 1).
case_images: Fundus color photograph (left) and fluorescein angiography (right) of the right eye.. Notes: (A) Initial presentation. (B) Three years and 7 months after starting infliximab. (C) Five months after starting adalimumab. Vitreous haze was apparent at the first examination (A, left), but disappeared after starting infliximab (B, left) and did not reappear after switching to adalimumab (C, left). Leakage from retinal vessels was seen in fluorescein angiography examination before treatment (A, right), but improved with infliximab (B, right) and adalimumab (C, right).
case_images: imcrj-9-301Fig2.jpg
case_images: PMC5045905_01_imcrj-9-301Fig2.jpg
case_images: f2-imcrj-9-301
case_images: Fluorescein angiography examination showed leakage from retinal vessels at the first examination, but this leakage was dramatically improved by infliximab, and the improvement was maintained on adalimumab (Figure 2).